– UK, London – Verona Pharma plc (Nasdaq: VRNA | LON: VRP), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced the appointment of Lisa Deschamps to its board as a Non-Executive Director, effective March 1, 2021.
“We are delighted to welcome Lisa to the Board,” said Board chair, Dr. David Ebsworth. “Her wealth of leadership, strategic and commercial expertise will be valuable as we progress ensifentrine through Phase 3 trials and prepare for commercialization.”
About Lisa Deschamps
Ms. Deschamps is SVP, Chief Business Officer, of Novartis Gene Therapies where she is responsible for strategic planning and worldwide commercialization of pipeline and in-market assets across the gene therapy portfolio. This includes managing significant revenue growth targets and profitability margins worldwide.
Before this role, Ms. Deschamps was the Head of the Global Neuroscience Franchise. During her 25-year career at Novartis, she has successfully brought small molecules, biologics, and gene therapies from the clinic to commercialization. Throughout her tenure, Ms. Deschamps has gained significant global and US experience in bringing respiratory and other specialized therapeutic area products to the marketplace. Also, she has extensive experience in the exploration of potential acquisition and partnering opportunities.
Ms. Deschamps serves on several commercial and development executive teams within the Novartis enterprise. She has an MBA in General Management from NYU Stern School of Business and a BBA in marketing from IONA College, Hagan School of Business.
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE for COPD maintenance treatment. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler and pressurized metered-dose inhaler. Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma, and other respiratory diseases.
For more information: https://www.veronapharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
